Immediately after the Arizona Cardinals selected running back Jeremiyah Love with the third overall pick in the 2024 NFL Draft, Ian Rapoport of NFL Network shared a previously undisclosed medical detail.

According to Rapoport, Love had an abnormal EKG at the NFL Scouting Combine. The issue was later cleared through additional testing, and it did not affect Love’s draft stock.

Rapoport’s revelation sparked discussions about transparency in player evaluations. Many questioned why this information was not disclosed earlier, given its relevance to Love’s medical history.

The incident highlights the NFL’s rigorous medical screening process and the scrutiny players face during the draft process. Despite the initial concern, Love’s selection at No. 3 overall suggests teams were confident in his long-term health.

NFL teams rely on comprehensive medical evaluations to assess player risks. While Love’s case was resolved, it raises questions about the timing and communication of such findings in future drafts.